NeoGenomics, Inc. (NEO) Insider Robert J. Shovlin Sells 186,014 Shares

NeoGenomics, Inc. (NASDAQ:NEO) insider Robert J. Shovlin sold 186,014 shares of the company’s stock in a transaction that occurred on Wednesday, February 27th. The stock was sold at an average price of $18.96, for a total value of $3,526,825.44. Following the sale, the insider now owns 40,166 shares of the company’s stock, valued at approximately $761,547.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

NASDAQ NEO traded down $0.02 during trading hours on Friday, hitting $19.58. 29,548 shares of the company’s stock were exchanged, compared to its average volume of 1,612,305. NeoGenomics, Inc. has a 12-month low of $7.71 and a 12-month high of $19.69. The company has a market capitalization of $1.85 billion, a PE ratio of 150.46 and a beta of 0.79. The company has a current ratio of 1.70, a quick ratio of 3.98 and a debt-to-equity ratio of 0.31.

NeoGenomics (NASDAQ:NEO) last released its earnings results on Tuesday, February 19th. The medical research company reported $0.06 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.02. NeoGenomics had a return on equity of 2.25% and a net margin of 0.95%. The firm had revenue of $76.50 million for the quarter, compared to the consensus estimate of $71.29 million. During the same period in the prior year, the business posted $0.05 earnings per share. The firm’s revenue for the quarter was up 24.6% compared to the same quarter last year. Equities analysts predict that NeoGenomics, Inc. will post 0.18 EPS for the current year.

Several research firms have recently commented on NEO. Benchmark set a $22.00 price target on NeoGenomics and gave the stock a “buy” rating in a research note on Thursday, November 1st. BidaskClub raised NeoGenomics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 20th. Zacks Investment Research raised NeoGenomics from a “hold” rating to a “strong-buy” rating and set a $21.00 price objective on the stock in a research note on Saturday, November 3rd. Raymond James reaffirmed a “buy” rating and set a $24.00 price objective on shares of NeoGenomics in a research note on Tuesday, December 4th. Finally, Scotiabank reaffirmed an “average” rating and set a $24.00 price objective on shares of NeoGenomics in a research note on Friday, November 16th. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $19.33.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. CWM LLC purchased a new position in shares of NeoGenomics in the 4th quarter worth about $30,000. Ruggie Capital Group raised its holdings in shares of NeoGenomics by 74.1% in the 4th quarter. Ruggie Capital Group now owns 2,350 shares of the medical research company’s stock worth $30,000 after purchasing an additional 1,000 shares during the period. First Quadrant L P CA purchased a new position in shares of NeoGenomics in the 4th quarter worth about $65,000. Quantamental Technologies LLC purchased a new position in shares of NeoGenomics in the 4th quarter worth about $76,000. Finally, Bessemer Group Inc. purchased a new position in shares of NeoGenomics in the 4th quarter worth about $78,000. Hedge funds and other institutional investors own 83.22% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://transcriptdaily.com/2019/03/01/neogenomics-inc-neo-insider-robert-j-shovlin-sells-186014-shares.html.

About NeoGenomics

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.

Featured Article: How do candlesticks reflect price movement?

Insider Buying and Selling by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply